Assembly Biosciences logo
Assembly Biosciences ASMB
$ 22.74 0.89%
report update icon

Quarterly report 2026-Q2
added 08-13-2026

Assembly Biosciences EPS Ratio | ASMB

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.

Calculated as:

EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio Assembly Biosciences

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2005
-0.55 -6.69 -13.4 -23.1 -3 -1.75 -3.72 -3.98 -2.41 -2.57 -1.81 -3.4 -5 -1.94 -3.57 -24.7 -10 - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
-0.55 -24.7 -6.56

Quarterly EPS Ratio Assembly Biosciences

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
-1.33 -0.54 - -0.72 -1.33 -1.17 - -1.51 -1.98 -1.66 - -3.29 -3.88 -4.46 - -0.48 -0.51 -0.48 - -0.41 -0.55 -0.69 -1.11 -0.09 0.21 -0.76 -0.99 -0.96 -0.72 -1.05 -1.03 -0.87 -1.3 -0.8 -160 -710 -780 -810 -0.67 -0.67 -0.59 -0.64 -0.45 -0.38 -0.41 -0.64 - -1.33 -0.52 -0.92 - -1.23 -1.2 -0.22 -0.29 -0.41 -0.59 -0.66 -1.52 -0.5 -0.97 -0.38

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
0.21 -810 -45.6

References

  1. Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer EPS Ratio Price % 24h Market Cap Country
Athira Pharma Athira Pharma
ATHA
-24.7 - - $ 269 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
-0.93 - -52.27 % $ 4.45 M usaUSA
AVROBIO AVROBIO
AVRO
-4.05 - 1083.1 % $ 745 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
6.6 - - $ 96.9 B britainBritain
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
-1.11 - -2.5 % $ 5.88 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
0.2 - 0.49 % $ 251 B cayman-islandsCayman-islands
Bio-Path Holdings Bio-Path Holdings
BPTH
-4.12 - - $ 100 K usaUSA
Cara Therapeutics Cara Therapeutics
CARA
-2.46 - -3.03 % $ 260 M usaUSA
ChromaDex Corporation ChromaDex Corporation
CDXC
0.22 - -0.88 % $ 598 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
-1.91 - -16.75 % $ 25.8 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCC
-6.45 - -5.98 % $ 34.1 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
-6.45 - -4.36 % $ 27 M usaUSA
Diffusion Pharmaceuticals Diffusion Pharmaceuticals
DFFN
-2.98 - 11.68 % $ 8.97 M usaUSA
Eloxx Pharmaceuticals Eloxx Pharmaceuticals
ELOX
-0.86 - -5.68 % $ 8.28 M usaUSA
Enochian Biosciences Enochian Biosciences
ENOB
-1.08 - - $ 40.5 M usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
-0.11 - - $ 661 M usaUSA
Evofem Biosciences Evofem Biosciences
EVFM
-0.11 - 7.55 % $ 38.1 M usaUSA
Eyenovia Eyenovia
EYEN
-9.4 - 49.81 % $ 13.2 M usaUSA
FibroGen FibroGen
FGEN
45.4 - - $ 889 M usaUSA
Homology Medicines Homology Medicines
FIXX
2.42 - 0.77 % $ 53.4 M usaUSA
Amicus Therapeutics Amicus Therapeutics
FOLD
-0.09 - - $ 4.47 B usaUSA
Frequency Therapeutics Frequency Therapeutics
FREQ
-12.5 - - $ 528 M usaUSA
Galecto Galecto
GLTO
3.98 - - $ 762 M danmarkDanmark
GlycoMimetics GlycoMimetics
GLYC
-0.59 - 9357.83 % $ 1.01 B usaUSA
Graybug Vision Graybug Vision
GRAY
-1.97 - -11.23 % $ 9.65 M usaUSA
Galera Therapeutics Galera Therapeutics
GRTX
0.64 - -32.59 % $ 7.61 M usaUSA
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
0.75 - 1.35 % $ 17.8 M chinaChina
Hepion Pharmaceuticals Hepion Pharmaceuticals
HEPA
-0.88 - -18.79 % $ 39.3 K usaUSA
Hoth Therapeutics Hoth Therapeutics
HOTH
-0.9 - - $ 18.8 M usaUSA
IMARA IMARA
IMRA
-1.83 - 15.96 % $ 663 M usaUSA
KalVista Pharmaceuticals KalVista Pharmaceuticals
KALV
-2.03 - - $ 1.45 B britainBritain
KemPharm KemPharm
KMPH
1.4 - -0.34 % $ 200 M usaUSA
Kezar Life Sciences Kezar Life Sciences
KZR
-7.66 - - $ 53.3 M usaUSA
Lixte Biotechnology Holdings Lixte Biotechnology Holdings
LIXT
-1.59 - - $ 63.4 M usaUSA
Magenta Therapeutics Magenta Therapeutics
MGTA
-4.2 - -7.74 % $ 41.6 M usaUSA
NovaBay Pharmaceuticals NovaBay Pharmaceuticals
NBY
-108 - - $ 11.3 M usaUSA
NeuroBo Pharmaceuticals NeuroBo Pharmaceuticals
NRBO
-7.35 - 0.43 % $ 12 M usaUSA
OncoCyte Corporation OncoCyte Corporation
OCX
-1.65 - 17.22 % $ 355 K usaUSA
Onconova Therapeutics Onconova Therapeutics
ONTX
0.83 - -0.47 % $ 21 M usaUSA
Opthea Limited Opthea Limited
OPT
-0.133 - - $ 1.2 B australiaAustralia
BiomX BiomX
PHGE
22.2 $ 1.85 14.2 % $ 3.02 M israelIsrael
Pieris Pharmaceuticals Pieris Pharmaceuticals
PIRS
-3.71 - -15.58 % $ 1.22 B germanyGermany
Plus Therapeutics Plus Therapeutics
PSTV
-0.29 - - $ 301 M usaUSA
Pluristem Therapeutics Pluristem Therapeutics
PSTI
-2.44 - -1.9 % $ 33.3 M israelIsrael
Qualigen Therapeutics Qualigen Therapeutics
QLGN
-8.11 - 5.59 % $ 1.16 M usaUSA
Qilian International Holding Group Limited Qilian International Holding Group Limited
QLI
-0.18 - -6.08 % $ 184 M chinaChina
Cassava Sciences Cassava Sciences
SAVA
-1.88 - - $ 110 M usaUSA
Selecta Biosciences Selecta Biosciences
SELB
-5.02 - -8.69 % $ 126 M usaUSA
Sangamo Therapeutics Sangamo Therapeutics
SGMO
-0.44 - - $ 50.4 M usaUSA
Salarius Pharmaceuticals Salarius Pharmaceuticals
SLRX
-129 - - $ 2.64 M usaUSA